Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Jun 2021
Historique:
received: 06 05 2021
revised: 04 06 2021
accepted: 08 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 15 7 2021
Statut: epublish

Résumé

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden. However, mutations in oncogenic drivers such as

Identifiants

pubmed: 34208111
pii: ijms22126288
doi: 10.3390/ijms22126288
pmc: PMC8230861
pii:
doi:

Substances chimiques

B7-H1 Antigen 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Oncoimmunology. 2017 Jul 26;6(11):e1356145
pubmed: 29147605
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Thorac Oncol. 2018 Aug;13(8):1146-1155
pubmed: 29730379
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Front Immunol. 2020 Nov 25;11:527750
pubmed: 33324391
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
pubmed: 23610105
Lung Cancer. 2018 Oct;124:117-124
pubmed: 30268448
Clin Lung Cancer. 2019 Nov;20(6):e593-e596
pubmed: 31395437
Lung Cancer. 2020 Feb;140:8-18
pubmed: 31838169
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
J Manag Care Spec Pharm. 2020 Aug;26(8):981-986
pubmed: 32329651
Clin Lung Cancer. 2020 Jul 15;:
pubmed: 32807653
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
J Surg Res. 2018 Oct;230:181-185
pubmed: 30072189
J Thorac Oncol. 2020 Apr;15(4):628-636
pubmed: 31945494
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Target Oncol. 2017 Oct;12(5):563-569
pubmed: 28624922
J Clin Oncol. 2017 Aug 10;35(23):2613-2618
pubmed: 28520527
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
Clin Lung Cancer. 2021 Jan 7;:
pubmed: 33582070
Ann Oncol. 2017 Feb 1;28(2):292-297
pubmed: 27803005
Lancet Oncol. 2016 Dec;17(12):1653-1660
pubmed: 27825636
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Ann Oncol. 2020 May;31(5):599-608
pubmed: 32178965
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
J Thorac Oncol. 2021 May;16(5):868-872
pubmed: 33539970
Semin Intervent Radiol. 2013 Jun;30(2):93-8
pubmed: 24436524
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Cancer Treat Rev. 2018 Dec;71:47-58
pubmed: 30359792
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641
pubmed: 27956436
Cancer Discov. 2021 Feb 25;:
pubmed: 33632775
Lung Cancer. 2013 Nov;82(2):179-89
pubmed: 24011633
Virchows Arch. 2020 Aug;477(2):207-217
pubmed: 31989260
Crit Rev Oncol Hematol. 2021 Jan;157:103194
pubmed: 33316418
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Lung Cancer. 2018 Apr;118:36-40
pubmed: 29572000
J Thorac Oncol. 2018 Aug;13(8):1138-1145
pubmed: 29874546
Oncoimmunology. 2020 Apr 12;9(1):1744898
pubmed: 33457089
J Thorac Oncol. 2017 May;12(5):878-883
pubmed: 28104537
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Anticancer Drugs. 2019 Jun;30(5):537-541
pubmed: 30762593
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Chest Med. 2011 Dec;32(4):605-44
pubmed: 22054876
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Ann Oncol. 2014 Oct;25(10):1935-1940
pubmed: 25009014
Eur J Cancer. 2019 Mar;109:28-35
pubmed: 30685684
Lancet Oncol. 2013 Sep;14(10):953-61
pubmed: 23948351
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Lung Cancer. 2018 Nov;125:86-92
pubmed: 30429043
JAMA Oncol. 2020 May 1;6(5):661-674
pubmed: 32271377
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Cancer Med. 2019 Apr;8(4):1521-1529
pubmed: 30790471
Cancer Biol Med. 2018 Nov;15(4):434-442
pubmed: 30766753
Ann Oncol. 2017 Jul 1;28(7):1532-1539
pubmed: 28407039
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
Oncotarget. 2015 Jun 10;6(16):14209-19
pubmed: 25895031
PLoS Med. 2008 Sep 30;5(9):e185
pubmed: 18788891
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
J Thorac Oncol. 2018 Aug;13(8):1128-1137
pubmed: 29723688
Cancer Discov. 2015 Aug;5(8):842-9
pubmed: 25971939
Thorac Cancer. 2021 Jan;12(2):218-226
pubmed: 33210451
J Thorac Oncol. 2017 Feb;12(2):403-407
pubmed: 27765535
Cancer Discov. 2013 Dec;3(12):1330-2
pubmed: 24327693
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Ann Oncol. 2016 Feb;27(2):281-6
pubmed: 26598547
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Lancet Oncol. 2020 Feb;21(2):261-270
pubmed: 31838015
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Cancer Res Treat. 2018 Jan;50(1):95-102
pubmed: 28301925
Clin Cancer Res. 2019 Feb 1;25(3):1063-1069
pubmed: 30045933

Auteurs

Edouard Dantoing (E)

Department of Pneumology, CHU Rouen, 76000 Rouen, France.

Nicolas Piton (N)

Department of Pathology, CHU Rouen, 76000 Rouen, France.

Mathieu Salaün (M)

Department of Pneumology, CHU Rouen, 76000 Rouen, France.
QuantIF Team, LITIS Lab EA4108, UNIROUEN, Normandie University, 76000 Rouen, France.
Inserm CIC CRB 1404, CHU Rouen, 76000 Rouen, France.

Luc Thiberville (L)

Department of Pneumology, CHU Rouen, 76000 Rouen, France.
QuantIF Team, LITIS Lab EA4108, UNIROUEN, Normandie University, 76000 Rouen, France.
Inserm CIC CRB 1404, CHU Rouen, 76000 Rouen, France.

Florian Guisier (F)

Department of Pneumology, CHU Rouen, 76000 Rouen, France.
QuantIF Team, LITIS Lab EA4108, UNIROUEN, Normandie University, 76000 Rouen, France.
Inserm CIC CRB 1404, CHU Rouen, 76000 Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH